Safety and Efficacy of HSP90 Inhibitor Ganetespib for Neoadjuvant Treatment of Stage II/III Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
NPJ Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
NPJ Breast Cancer 2022 Dec 01;8(1)128, JE Lang, A Forero-Torres, D Yee, C Yau, D Wolf, J Park, BA Parker, AJ Chien, AM Wallace, R Murthy, KS Albain, ED Ellis, H Beckwith, BB Haley, AD Elias, JC Boughey, RL Yung, C Isaacs, AS Clark, HS Han, R Nanda, QJ Khan, KK Edmiston, E Stringer-Reasor, E Price, B Joe, MC Liu, L Brown-Swigart, EF Petricoin, JD Wulfkuhle, M Buxton, JL Clennell, A Sanil, S Berry, SM Asare, A Wilson, GL Hirst, R Singhrao, AL Asare, JB Matthews, M Melisko, J Perlmutter, HS Rugo, WF Symmans, LJ van 't Veer, NM Hylton, AM DeMichele, DA Berry, LJ EssermanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.